{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:47:07Z","timestamp":1791499627804,"version":"4.3.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.modpat.2023.100120","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T03:56:48Z","timestamp":1675310208000},"page":"100120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5015-8437","authenticated-orcid":false,"given":"Fidele Y.","family":"Musangile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibu","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Sagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurina","family":"Mikasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiyoshi","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9862-3051","authenticated-orcid":false,"given":"Shin-ichi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.modpat.2023.100120_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.modpat.2023.100120_bib2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"issue":"15","key":"10.1016\/j.modpat.2023.100120_bib3","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1158\/0008-5472.CAN-06-1182","article-title":"PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors","volume":"66","author":"L\u00f3pez-Knowles","year":"2006","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.modpat.2023.100120_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.modpat.2023.100120_bib5","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1309\/AJCPACNUDWEN9GN4","article-title":"Molecular and immunohistologic analyses cannot reliably solve diagnostic variation of flat intraepithelial lesions of the urinary bladder","volume":"134","author":"Murata","year":"2010","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"10.1016\/j.modpat.2023.100120_bib6","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/s41379-022-01087-7","article-title":"Flat intraurothelial lesions of the urinary bladder-do hyperplasia, dysplasia, and atypia of unknown significance need to exist as diagnostic entities? and how to handle in routine clinical practice","volume":"35","author":"Paner","year":"2022","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2023.100120_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0094-0143(05)70229-9","article-title":"The natural history of bladder cancer. Implications for therapy","volume":"27","author":"Lee","year":"2000","journal-title":"Urol Clin North Am"},{"issue":"1","key":"10.1016\/j.modpat.2023.100120_bib8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.modpat.2023.100120_bib9","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"issue":"7492","key":"10.1016\/j.modpat.2023.100120_bib10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.modpat.2023.100120_bib11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/ng.907","article-title":"Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder","volume":"43","author":"Gui","year":"2011","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.modpat.2023.100120_bib12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: Prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.modpat.2023.100120_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.modpat.2023.100120_bib14","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ccell.2017.08.005","article-title":"Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency","volume":"32","author":"Hurst","year":"2017","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.modpat.2023.100120_bib15","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.modpat.2023.100120_bib16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ajpath.2019.10.004","article-title":"Next-generation sequencing reveals potential predictive biomarkers and targets of therapy for urothelial carcinoma in situ of the urinary bladder","volume":"190","author":"Garczyk","year":"2020","journal-title":"Am J Pathol"},{"issue":"7739","key":"10.1016\/j.modpat.2023.100120_bib17","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41586-018-0811-x","article-title":"Age-related remodelling of oesophageal epithelia by mutated cancer drivers","volume":"565","author":"Yokoyama","year":"2019","journal-title":"Nature"},{"issue":"6512","key":"10.1016\/j.modpat.2023.100120_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1126\/science.aba8347","article-title":"Extensive heterogeneity in somatic mutation and selection in the human bladder","volume":"370","author":"Lawson","year":"2020","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.modpat.2023.100120_bib19","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0002-9440(10)64665-2","article-title":"Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors","volume":"158","author":"Billerey","year":"2001","journal-title":"Am J Pathol"},{"issue":"9","key":"10.1016\/j.modpat.2023.100120_bib20","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1002\/ijc.24619","article-title":"Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development","volume":"125","author":"Zieger","year":"2009","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.modpat.2023.100120_bib21","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.modpat.2023.100120_bib22","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2020.38.6_suppl.434","article-title":"The emerging target KRAS G12C in genitourinary malignancies","volume":"38","author":"Grivas","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.modpat.2023.100120_bib23","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1007\/s11033-013-2512-8","article-title":"The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer","volume":"40","author":"Ouerhani","year":"2013","journal-title":"Mol Biol Rep"},{"issue":"8","key":"10.1016\/j.modpat.2023.100120_bib24","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00345-022-04061-9","article-title":"Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer","volume":"40","author":"Carrasco","year":"2022","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.modpat.2023.100120_bib25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1464-410X.1983.tb03400.x","article-title":"Prognostic significance of biopsy results of normal-looking mucosa in cases of superficial bladder cancer","volume":"55","author":"Smith","year":"1983","journal-title":"Br J Urol"},{"issue":"3","key":"10.1016\/j.modpat.2023.100120_bib26","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.bjc.6601954","article-title":"Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb","volume":"91","author":"Hitchings","year":"2004","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.modpat.2023.100120_bib27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1308\/003588410X12664192076935","article-title":"Mechanisms of recurrence of Ta\/T1 bladder cancer","volume":"92","author":"Bryan","year":"2010","journal-title":"Ann R Coll Surg Engl"},{"issue":"20","key":"10.1016\/j.modpat.2023.100120_bib28","doi-asserted-by":"crossref","first-page":"8169","DOI":"10.1158\/0008-5472.CAN-10-1335","article-title":"Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue","volume":"70","author":"Wolff","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.modpat.2023.100120_bib29","series-title":"Pathology and genetics of tumours of the urinary system and male genital organs World Health Organization Classification of Tumours Lyon IARC Press 2004 Search in","author":"Ji","year":"2004"},{"issue":"4","key":"10.1016\/j.modpat.2023.100120_bib30","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0002-9440(10)64388-X","article-title":"Identification of chromosome 9 alterations and p53 accumulation in isolated carcinoma in situ of the urinary bladder versus carcinoma in situ associated with carcinoma","volume":"161","author":"Hopman","year":"2002","journal-title":"Am J Pathol"},{"issue":"12","key":"10.1016\/j.modpat.2023.100120_bib31","article-title":"Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight","volume":"2","author":"Hurst","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.modpat.2023.100120_bib32","article-title":"Somatic mutations in HER2 and implications for current treatment paradigms in HER2-positive breast cancer","volume":"2020","author":"Gaibar","year":"2020","journal-title":"J\u00a0Oncol"},{"issue":"36","key":"10.1016\/j.modpat.2023.100120_bib33","doi-asserted-by":"crossref","first-page":"14476","DOI":"10.1073\/pnas.1203201109","article-title":"Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2","volume":"109","author":"Greulich","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.modpat.2023.100120_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2021.06.021","article-title":"High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer","volume":"40","author":"Sikic","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.modpat.2023.100120_bib35","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1186\/s12885-016-2703-5","article-title":"Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques","volume":"16","author":"Nedjadi","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.modpat.2023.100120_bib36","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1200\/PO.20.00256","article-title":"Comprehensive clinical and molecular characterization of KRAS G12C-mutant colorectal cancer","volume":"5","author":"Henry","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"10.1016\/j.modpat.2023.100120_bib37","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jtho.2021.02.016","article-title":"Prognostic impact of KRAS G12C mutation in patients with NSCLC: Results from the European Thoracic Oncology Platform Lungscape Project","volume":"16","author":"Finn","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2023.100120_bib38","first-page":"1120","article-title":"Targeting HER2 with T-DM1, an antibody cytotoxic drug conjugate, is effective in HER2 over expressing bladder cancer","volume":"194","author":"Hayashi","year":"2015","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.modpat.2023.100120_bib39","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1158\/1541-7786.MCR-20-0751","article-title":"Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes","volume":"19","author":"Alhalabi","year":"2021","journal-title":"Mol Cancer Res"},{"issue":"13","key":"10.1016\/j.modpat.2023.100120_bib40","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS G12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.modpat.2023.100120_bib41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13046-021-02225-w","article-title":"The path to the clinic: a comprehensive review on direct KRAS G12C inhibitors","volume":"41","author":"Kwan","year":"2022","journal-title":"J\u00a0Exp Clin Cancer Res"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089339522300025X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089339522300025X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:23:57Z","timestamp":1760232237000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089339522300025X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S089339522300025X"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100120","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100120"}}